TNSN04120A1 - Derives de 5-(pyridin-3-yl)-1-azabicyclo [3.2.1] octane, leur preparation et leur application en therapeutique - Google Patents
Derives de 5-(pyridin-3-yl)-1-azabicyclo [3.2.1] octane, leur preparation et leur application en therapeutiqueInfo
- Publication number
- TNSN04120A1 TNSN04120A1 TNP2004000120A TNSN04120A TNSN04120A1 TN SN04120 A1 TNSN04120 A1 TN SN04120A1 TN P2004000120 A TNP2004000120 A TN P2004000120A TN SN04120 A TNSN04120 A TN SN04120A TN SN04120 A1 TNSN04120 A1 TN SN04120A1
- Authority
- TN
- Tunisia
- Prior art keywords
- group
- azabicyclo
- pyridin
- octane
- derivatives
- Prior art date
Links
- DOGNRXAZCRIVQB-UHFFFAOYSA-N 5-pyridin-3-yl-1-azabicyclo[3.2.1]octane Chemical class C1N(CCC2)CCC21C1=CC=CN=C1 DOGNRXAZCRIVQB-UHFFFAOYSA-N 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- -1 PHENYL GROUP Chemical group 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical class N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 abstract 1
- WZKSXHQDXQKIQJ-UHFFFAOYSA-N F[C](F)F Chemical class F[C](F)F WZKSXHQDXQKIQJ-UHFFFAOYSA-N 0.000 abstract 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 abstract 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 abstract 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical class O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract 1
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 abstract 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0200109A FR2834511B1 (fr) | 2002-01-07 | 2002-01-07 | Derives de 5-(pyridin-3-yl)-1-azabicyclo[3.2.1]octane, leur preparation et leur application en therapeutique |
| PCT/FR2003/000004 WO2003057697A1 (fr) | 2002-01-07 | 2003-01-03 | Derives de 5-(pyridin-3-yl)-1-azabicyclo [3.2.1] octane, leur preparation et leur application en therapeutique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TNSN04120A1 true TNSN04120A1 (fr) | 2006-06-01 |
Family
ID=8871176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNP2004000120A TNSN04120A1 (fr) | 2002-01-07 | 2004-06-30 | Derives de 5-(pyridin-3-yl)-1-azabicyclo [3.2.1] octane, leur preparation et leur application en therapeutique |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US7223750B2 (https=) |
| EP (1) | EP1465893B1 (https=) |
| JP (1) | JP4402957B2 (https=) |
| KR (1) | KR100977332B1 (https=) |
| CN (2) | CN1911928A (https=) |
| AR (2) | AR038098A1 (https=) |
| AT (1) | ATE355290T1 (https=) |
| AU (1) | AU2003216777B2 (https=) |
| BR (1) | BR0306707A (https=) |
| CA (1) | CA2471628C (https=) |
| CO (1) | CO5590914A2 (https=) |
| CY (1) | CY1106580T1 (https=) |
| DE (1) | DE60312123T2 (https=) |
| DK (1) | DK1465893T3 (https=) |
| EA (1) | EA007793B1 (https=) |
| EC (1) | ECSP045176A (https=) |
| ES (1) | ES2281631T3 (https=) |
| FR (1) | FR2834511B1 (https=) |
| HR (1) | HRP20040617B1 (https=) |
| IL (2) | IL162524A0 (https=) |
| IS (1) | IS2470B (https=) |
| MA (1) | MA27165A1 (https=) |
| ME (2) | ME00213B (https=) |
| MX (1) | MXPA04006630A (https=) |
| NO (1) | NO329309B1 (https=) |
| NZ (1) | NZ533793A (https=) |
| PL (1) | PL216665B1 (https=) |
| PT (1) | PT1465893E (https=) |
| RS (1) | RS50921B (https=) |
| SI (1) | SI1465893T1 (https=) |
| TN (1) | TNSN04120A1 (https=) |
| TW (1) | TWI336703B (https=) |
| UA (1) | UA77229C2 (https=) |
| WO (1) | WO2003057697A1 (https=) |
| ZA (1) | ZA200405002B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9902007D0 (en) * | 1999-01-30 | 1999-03-17 | Thomas Carpentry Services Limi | Improvements relating to door frames |
| FR2834511B1 (fr) * | 2002-01-07 | 2004-02-13 | Sanofi Synthelabo | Derives de 5-(pyridin-3-yl)-1-azabicyclo[3.2.1]octane, leur preparation et leur application en therapeutique |
| FR2889701B1 (fr) * | 2005-08-12 | 2007-10-05 | Sanofi Aventis Sa | Derives de 5-pyridinyl-1-azabicyclo[3.2.1]octane, leur preparation en therapeutique. |
| FR2889847B1 (fr) | 2005-08-18 | 2007-10-05 | Sanofi Aventis Sa | Derives de 5-pyridazinyl-1-azabicyclo[3.2.1]octave, leur preparation en therapeutique. |
| FR2912404B1 (fr) * | 2007-02-09 | 2009-04-10 | Sanofi Aventis Sa | Derives d'azabicycloalkane,leur preparation et leur application en therapeutique. |
| KR101928505B1 (ko) | 2011-01-28 | 2018-12-12 | 에스케이바이오팜 주식회사 | 피리돈 유도체 및 이를 포함하는 약학적 조성물 |
| KR101925971B1 (ko) * | 2011-01-28 | 2018-12-06 | 에스케이바이오팜 주식회사 | 피리돈 유도체 및 이를 포함하는 약학적 조성물 |
| WO2019087149A1 (en) | 2017-11-03 | 2019-05-09 | Novartis Ag | Azabicyclo and diazepine derivatives for treating ocular disorders |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5817679A (en) * | 1993-04-01 | 1998-10-06 | University Of Virginia | 7-Azabicyclo 2.2.1!-heptane and -heptene derivatives as cholinergic receptor ligands |
| AU7474794A (en) | 1993-07-22 | 1995-02-20 | E.I. Du Pont De Nemours And Company | Arthropodicidal azacyclic heterocycles |
| FR2786769B1 (fr) * | 1998-12-04 | 2002-10-25 | Synthelabo | Derives de 2,5-diazabicyclo[2.2.1]heptane, leur preparation et leur application en therapeutique |
| FR2786770B1 (fr) * | 1998-12-04 | 2001-01-19 | Synthelabo | Derives de 1,4-diazabicyclo[3.2.2.]nonane, leur preparation et leur application en therapeutique |
| FR2834511B1 (fr) * | 2002-01-07 | 2004-02-13 | Sanofi Synthelabo | Derives de 5-(pyridin-3-yl)-1-azabicyclo[3.2.1]octane, leur preparation et leur application en therapeutique |
-
2002
- 2002-01-07 FR FR0200109A patent/FR2834511B1/fr not_active Expired - Fee Related
- 2002-12-31 TW TW091138055A patent/TWI336703B/zh not_active IP Right Cessation
-
2003
- 2003-01-03 RS YUP-599/04A patent/RS50921B/sr unknown
- 2003-01-03 MX MXPA04006630A patent/MXPA04006630A/es active IP Right Grant
- 2003-01-03 AU AU2003216777A patent/AU2003216777B2/en not_active Ceased
- 2003-01-03 SI SI200330774T patent/SI1465893T1/sl unknown
- 2003-01-03 AT AT03712202T patent/ATE355290T1/de active
- 2003-01-03 KR KR1020047010566A patent/KR100977332B1/ko not_active Expired - Fee Related
- 2003-01-03 PL PL370065A patent/PL216665B1/pl unknown
- 2003-01-03 ES ES03712202T patent/ES2281631T3/es not_active Expired - Lifetime
- 2003-01-03 CA CA2471628A patent/CA2471628C/en not_active Expired - Fee Related
- 2003-01-03 NZ NZ533793A patent/NZ533793A/en not_active IP Right Cessation
- 2003-01-03 CN CNA2006101091747A patent/CN1911928A/zh active Pending
- 2003-01-03 US US10/500,015 patent/US7223750B2/en not_active Expired - Lifetime
- 2003-01-03 BR BR0306707-6A patent/BR0306707A/pt not_active Application Discontinuation
- 2003-01-03 WO PCT/FR2003/000004 patent/WO2003057697A1/fr not_active Ceased
- 2003-01-03 AR ARP030100009A patent/AR038098A1/es not_active Application Discontinuation
- 2003-01-03 ME MEP-2008-244A patent/ME00213B/me unknown
- 2003-01-03 IL IL16252403A patent/IL162524A0/xx unknown
- 2003-01-03 EP EP03712202A patent/EP1465893B1/fr not_active Expired - Lifetime
- 2003-01-03 DE DE60312123T patent/DE60312123T2/de not_active Expired - Lifetime
- 2003-01-03 PT PT03712202T patent/PT1465893E/pt unknown
- 2003-01-03 EA EA200400770A patent/EA007793B1/ru not_active IP Right Cessation
- 2003-01-03 HR HRP20040617AA patent/HRP20040617B1/hr not_active IP Right Cessation
- 2003-01-03 ME MEP-244/08A patent/MEP24408A/xx unknown
- 2003-01-03 JP JP2003558012A patent/JP4402957B2/ja not_active Expired - Fee Related
- 2003-01-03 CN CNB038019876A patent/CN1276921C/zh not_active Expired - Fee Related
- 2003-01-03 DK DK03712202T patent/DK1465893T3/da active
- 2003-03-01 UA UA20040605056A patent/UA77229C2/uk unknown
-
2004
- 2004-06-14 IL IL162524A patent/IL162524A/en not_active IP Right Cessation
- 2004-06-16 IS IS7322A patent/IS2470B/is unknown
- 2004-06-24 ZA ZA200405002A patent/ZA200405002B/en unknown
- 2004-06-29 EC EC2004005176A patent/ECSP045176A/es unknown
- 2004-06-30 TN TNP2004000120A patent/TNSN04120A1/fr unknown
- 2004-07-01 MA MA27759A patent/MA27165A1/fr unknown
- 2004-07-01 CO CO04062934A patent/CO5590914A2/es active IP Right Grant
- 2004-07-05 NO NO20042846A patent/NO329309B1/no not_active IP Right Cessation
-
2007
- 2007-04-05 US US11/696,993 patent/US7585974B2/en not_active Expired - Fee Related
- 2007-05-10 CY CY20071100641T patent/CY1106580T1/el unknown
-
2012
- 2012-05-28 AR ARP120101864A patent/AR086573A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2528920C (en) | Cyclo(hetero)alkenyl compounds useful for treating pain | |
| ATE205195T1 (de) | Imidazolderivate und ihre verwendung als farnesylproteintransferase inhibitoren | |
| MA27390A1 (fr) | Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique | |
| BR0014133A (pt) | Uso de um composto, composto, métodos de preparação de um composto, e para inibir aurora 2 quinase em um animal de sangue quente, e, composição farmacêutica | |
| BR0014137A (pt) | Composto, método para inibir a aurora 2 quinase em um animal de sangue quente, uso de um composto, e, composição farmacêutica | |
| DE69813896D1 (de) | Alpha-aminoamidderivate die als analgetische mittel nützlich sind | |
| EA199800882A1 (ru) | Производные замешенных индазолов, их применение в качестве ингибиторов фосфодиэстеразы (фдэ) iv и получение фактора некроза опухолей (фно) | |
| WO1999028304A3 (en) | Pdgf receptor kinase inhibitory compounds, their preparation and compositions | |
| EA200700099A1 (ru) | Производные пиридина | |
| BR0014116A (pt) | Uso de um composto, composto, métodos para preparação de um composto, e para inibir aurora 2 quinase em um animal de sangue quente, e, composição farmacêutica | |
| BR0014136A (pt) | Composto, uso do mesmo, métodos para a preparação de um composto, e para inibir aurora 2 quinase em um animal de sangue quente, e, composição farmacêutica | |
| BRPI0616799B8 (pt) | derivado de piridina e derivado de pirimidina, composições farmacêuticas, usos, inibidores de angiogênese, contra receptor de fator de crescimento de hepatócito e contra metástase de câncer, e agente antitumor | |
| BRPI0409110A (pt) | derivados de 4-(4-heterociclilalcoxi)fenil-1-(heterociclil-carboni l)piridina e compostos relacionados como antagonistas de histamina h3 para o tratamento de doenças neurológicas tais como alzheimer | |
| TNSN06439A1 (fr) | Derives de 2-carbamide -4-phenylthiazole, leur preparation et leur application en therapeutique | |
| BR9808552A (pt) | Composto tricìclico ou um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica | |
| TNSN04120A1 (fr) | Derives de 5-(pyridin-3-yl)-1-azabicyclo [3.2.1] octane, leur preparation et leur application en therapeutique | |
| DE60237528D1 (de) | Neue aminoazetidin-, aminopyrrolidin- und aminopiperidinderivative | |
| FR2856684A1 (fr) | Derives de diphenylpyridine, leur preparation et leur application en therapeutique | |
| BR0011127A (pt) | Derivados de 4-fenil-pirimidina | |
| CA2528764A1 (en) | Thiazoline derivatives as selective androgen receptor modulators (sarms) | |
| GB9711123D0 (en) | Novel cyanoguanidines | |
| BRPI0417308A (pt) | compostos, respectivo uso, composição farmacêutica, métodos de tratamento de distúrbios mediados pelo receptor mglur5 e de inibição da ativação de receptores mglur5 e processo de produção de compostos de piridila | |
| NO20003106L (no) | Akronycin-forbindelser, fremstilling derav samt farmasøytiske sammensetninger omfattende slike | |
| KR890008099A (ko) | 피리독살 히드라존 유도체 및 이것을 함유하는 약조성물 | |
| BR0212173A (pt) | Derivado de tieno [2,3-d] pirimidina, composição farmacêutica, uso de compostos de tieno[2,3-d]pirimidina ou um sal ou solvato deste farmaceuticamente aceitáveis, e, método para tratamento de distúrbios de fertilidade em pacientes em necessidade do mesmo |